Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
EMERYVILLE, Calif., March 04, 2016 -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2015 after the market close, and will host a corporate update conference call and webcast on Thursday, March 10th at 4:30 PM Eastern Time.
| Thursday, March 10th @ 4:30 PM Eastern Time/1:30 PM Pacific Time | |
| Toll Free: | 888-337-8198 |
| International: | 719-325-2308 |
| Conference ID: | 5464024 |
| Webcast: | http://public.viavid.com/index.php?id=118497 |
| Replays, available through March 24, 2016: | |
| Domestic: | 877-870-5176 |
| International: | 858-384-5517 |
| Conference ID: | 5464024 |
About Zogenix
Zogenix, Inc. (NASDAQ:ZGNX) is an innovative pharmaceutical company committed to providing unique therapeutic solutions for people living with rare and burdensome disease conditions. Our focused strategy centers on advancing late-stage, high-value products for CNS disorders that will significantly improve outcomes for patients and physicians.
For more information, visit www.zogenix.com.
CONTACT: Investors: Andrew McDonald Founding Partner, LifeSci Advisors LLC 646-597-6987 | [email protected]
